Prognostic implications and interaction of L1 methylation and p53 expression statuses in advanced gastric cancer.
Gastric cancer
LINE-1
Methylation
Prognosis
TP53
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
14 05 2019
14 05 2019
Historique:
received:
31
12
2018
accepted:
02
04
2019
entrez:
16
5
2019
pubmed:
16
5
2019
medline:
19
3
2020
Statut:
epublish
Résumé
TP53 is frequently mutated across various tissue types of cancers. In normal cells, long interspersed nuclear element-1 (LINE-1, L1) is mostly repressed by DNA methylation in its 5' untranslated region but is activated by DNA demethylation process during tumorigenesis. p53 is indispensable for maintaining genomic stability and plays its role in controlling genomic stability by repressing retrotransposon activity. However, it is unclear whether p53 regulates expression or methylation of L1 differently depending on the mutational status of TP53. Four hundred ninety cases of advanced gastric cancer (AGC) were analyzed for their statuses in p53 expression and L1 methylation using immunohistochemistry and pyrosequencing, respectively. Whether L1 methylation and expression statuses were differently affected by types of TP53 mutants was analyzed in gastric cancer cell line. By p53 immunohistochemistry, tumors were classified into 4 groups according to the intensity and extent of stained tumor nuclei. L1 methylation level was significantly higher in p53 expression group 1 than in the other groups in which L1 methylation level was similar (P < 0.001). Although L1 methylation and p53 expression statuses were associated with patient survival, multivariate analysis revealed that L1 methylation was an independent prognostic parameter. In in vitro analysis of AGS cells with the introduction of wild type or mutant types of TP53, L1 methylation level and activity were different depending on types of TP53 mutation. Findings suggest that L1 methylation level is affected by TP53 mutation status; although, L1 methylation status was an independent prognostic parameter in patients with AGC. Further study is required to elucidate the mechanism of how wild type or mutant p53 affects L1 activity and methylation status of L1 CpG island.
Sections du résumé
BACKGROUND
TP53 is frequently mutated across various tissue types of cancers. In normal cells, long interspersed nuclear element-1 (LINE-1, L1) is mostly repressed by DNA methylation in its 5' untranslated region but is activated by DNA demethylation process during tumorigenesis. p53 is indispensable for maintaining genomic stability and plays its role in controlling genomic stability by repressing retrotransposon activity. However, it is unclear whether p53 regulates expression or methylation of L1 differently depending on the mutational status of TP53. Four hundred ninety cases of advanced gastric cancer (AGC) were analyzed for their statuses in p53 expression and L1 methylation using immunohistochemistry and pyrosequencing, respectively. Whether L1 methylation and expression statuses were differently affected by types of TP53 mutants was analyzed in gastric cancer cell line.
RESULTS
By p53 immunohistochemistry, tumors were classified into 4 groups according to the intensity and extent of stained tumor nuclei. L1 methylation level was significantly higher in p53 expression group 1 than in the other groups in which L1 methylation level was similar (P < 0.001). Although L1 methylation and p53 expression statuses were associated with patient survival, multivariate analysis revealed that L1 methylation was an independent prognostic parameter. In in vitro analysis of AGS cells with the introduction of wild type or mutant types of TP53, L1 methylation level and activity were different depending on types of TP53 mutation.
CONCLUSIONS
Findings suggest that L1 methylation level is affected by TP53 mutation status; although, L1 methylation status was an independent prognostic parameter in patients with AGC. Further study is required to elucidate the mechanism of how wild type or mutant p53 affects L1 activity and methylation status of L1 CpG island.
Identifiants
pubmed: 31088544
doi: 10.1186/s13148-019-0661-x
pii: 10.1186/s13148-019-0661-x
pmc: PMC6518708
doi:
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Références
PLoS Genet. 2010 Oct 07;6(10):
pubmed: 20949108
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15056-61
pubmed: 17015838
Cell. 2012 Jan 20;148(1-2):244-58
pubmed: 22265415
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Ann Surg. 2013 Mar;257(3):449-55
pubmed: 23023202
Cancer Sci. 2011 Jan;102(1):166-74
pubmed: 21087350
Oncotarget. 2016 Oct 4;7(40):64910-64920
pubmed: 27626311
BMC Cancer. 2017 Aug 29;17(1):588
pubmed: 28851390
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Gastric Cancer. 2019 Jan;22(1):37-47
pubmed: 29926315
J Natl Cancer Inst. 2014 Sep 04;106(9):
pubmed: 25190725
Melanoma Res. 2009 Jun;19(3):146-55
pubmed: 19441164
Genes Dev. 2012 Apr 15;26(8):830-45
pubmed: 22508727
Nature. 2015 Sep 10;525(7568):206-11
pubmed: 26331536
Genes Dev. 2006 Jan 15;20(2):210-24
pubmed: 16418485
Ann Thorac Surg. 2013 Nov;96(5):1790-4
pubmed: 23998411
Oncogene. 2007 Apr 2;26(15):2226-42
pubmed: 17401432
J Cell Biol. 2011 Jan 24;192(2):209-18
pubmed: 21263025
Clin Cancer Res. 2010 Apr 15;16(8):2418-26
pubmed: 20371677
Cancer Res. 2005 Oct 1;65(19):8635-9
pubmed: 16204030
Br J Surg. 2000 Feb;87(2):236-42
pubmed: 10671934
Nucleic Acids Res. 2005 Dec 02;33(21):6823-36
pubmed: 16326863
Oncogene. 2004 Nov 18;23(54):8841-6
pubmed: 15480421
Br J Cancer. 2019 Apr;120(8):797-805
pubmed: 30894685
Gastric Cancer. 2016 Jan;19(1):98-106
pubmed: 25609453
Nat Commun. 2013;4:2935
pubmed: 24343302
Clin Epigenetics. 2017 Jan 13;9:1
pubmed: 28149329
Genes Dev. 2016 Jan 1;30(1):64-77
pubmed: 26701264
Int J Cancer. 2012 Sep 1;131(5):1169-78
pubmed: 22038927
Oncogene. 2009 Nov 5;28(44):3857-65
pubmed: 19718052
Cancer Med. 2015 Jan;4(1):75-83
pubmed: 25354498
Nat Rev Cancer. 2006 Dec;6(12):909-23
pubmed: 17128209